Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials

被引:3
|
作者
Nishi, Takeshi [1 ]
Okada, Kozo [1 ]
Kitahara, Hideki [1 ]
Kameda, Ryo [1 ]
Ikutomi, Masayasu [1 ]
Imura, Shinji [1 ]
Hollak, M. Brooke [1 ]
Yock, Paul G. [1 ]
Popma, Jeffrey J. [2 ]
Kusano, Hajime [3 ]
Cheong, Wai-Fung [3 ]
Sudhir, Krishnankutty [3 ]
Fitzgerald, Peter J. [1 ]
Ellis, Stephen G. [4 ]
Kereiakes, Dean J. [5 ]
Stone, Gregg W. [6 ,7 ]
Honda, Yasuhiro [1 ]
Kimura, Takeshi [8 ]
机构
[1] Stanford Univ, Sch Med, Stanford Cardiovasc Inst, Div Cardiovasc Med, Stanford, CA 94305 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Abbott Vasc, Clin Sci & Med Affairs, Santa Clara, CA USA
[4] Cleveland Clin, Dept Cardiovasc Med, Heart & Vasc Inst, Cleveland, OH 44106 USA
[5] Christ Hosp Heart & Vasc Ctr, Lindner Res Ctr, Cincinnati, OH USA
[6] Cardiovasc Res Fdn, New York, NY USA
[7] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
[8] Kyoto Univ Hosp, Dept Cardiovasc Med, Kyoto, Japan
关键词
Intravascular ultrasound; Bioresorbable vascular scaffold; Drug-eluting stent; CORONARY-ARTERY-DISEASE; ELUTING STENT; CLINICAL-OUTCOMES; THROMBOSIS; STENOSIS; IMPACT;
D O I
10.1016/j.jjcc.2021.03.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The long-term prognostic impact of IVUS findings following Absorb BVS implantation re-mains uncertain. This study aimed to identify the IVUS predictors of long-term clinical outcomes follow-ing ABSORB bioresorbable vascular scaffold (BVS) implantation from the pooled IVUS substudy cohorts of the ABSORB III and Japan trials. Methods: A total of 298 lesions in 286 patients were enrolled with 2:1 randomization to ABSORB BVS vs. cobalt-chromium everolimus-eluting stents. This sub-analysis included 168 lesions of 160 patients in the Absorb arm whose post-procedural quantitative IVUS were available. The primary endpoint of this analysis was device-oriented composite endpoint (DOCE) of target lesion failure, including cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization. The median follow-up duration was 4.9 [3.1-5.0] years. Results: During follow-up, DOCE occurred in 10.1% of lesions treated with Absorb BVS. Among several post-procedural IVUS indices associated with DOCE, non-uniform device expansion (defined as unifor-mity index = minimum / maximum device area) (hazard ratio 0.47 per 0.1 increase [95%CI 0.28 to 0.77]; p = 0.003) and residual reference plaque burden (hazard ratio 4.01 per 10% increase [95%CI 1.50 to 10.77]; p = 0.006) were identified as independent predictors of DOCE by Cox multivariable analysis. Conclusions: Nonuniform device expansion and substantial untreated residual plaque in reference seg-ments were associated with long-term adverse events following BVS implantation. Baseline imaging to identify the appropriate device landing zone and procedural imaging to achieve uniform device expan-sion if possible (e.g. through post-dilatation) may improve clinical outcomes of BVS implantation. Clinical trial registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01751906 (ABSORB III); NCT01844284 (ABSORB Japan). (c) 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 50 条
  • [21] Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents Intravascular Ultrasound Assessment From the ABSORB II Trial
    Sotomi, Yohei
    Ishibashi, Yuki
    Suwannasom, Pannipa
    Nakatani, Shimpei
    Cho, Yun-Kyeong
    Grundeken, Maik J.
    Zeng, Yaping
    Tateishi, Hiroki
    Smits, Pieter C.
    Barragan, Paul
    Kornowski, Ran
    Gershlick, Anthony H.
    Windecker, Stephan
    van Geuns, Robert-Jan
    Bartorelli, Antonio L.
    de Winter, Robbert J.
    Tijssen, Jan
    Serruys, Patrick W.
    Onuma, Yoshinobu
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (12) : 1216 - 1227
  • [22] Optimal dual antiplatelet therapy duration for bioresorbable scaffolds: an individual patient data pooled analysis of the ABSORB trials
    Azzalini, Lorenzo
    Ellis, Stephen G.
    Kereiakes, Dean J.
    Kimura, Takeshi
    Gao, Runlin
    Onuma, Yoshinobu
    Chevalier, Bernard
    Dressler, Ovidiu
    Crowley, Aaron
    Zhou, Zhipeng
    Redfors, Bjorn
    Serruys, Patrick W.
    Stone, Gregg W.
    EUROINTERVENTION, 2021, 17 (12) : E981 - +
  • [23] Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry
    Baumbach, Andreas
    Zaman, Azfar
    West, Nick E. J.
    O'Kane, Peter
    Egred, Mohaned
    Johnson, Thomas
    Wheatcroft, Stephen
    Bowles, Ruth
    de Belder, Adam
    Bouras, Georgios
    Lansky, Alexandra
    Hill, Jonathan
    Mathur, Anthony
    de Belder, Mark A.
    Banning, Adrian P.
    EUROINTERVENTION, 2018, 13 (13) : 1554 - 1560
  • [24] Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials
    Shreenivas, Satya
    Kereiakes, Dean J.
    Ellis, Stephen G.
    Gao, Runlin
    Kimura, Takeshi
    Onuma, Yoshinobu
    Piard-Ruster, Karine
    Zhang, Yunlong
    Koo, Kai
    Minh-Thien Vu
    Serruys, Patrick W.
    Stone, Gregg W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (18) : 1881 - 1890
  • [25] Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up A Systematic Meta-analysis and Individual Patient Data Pooled Study
    Stone, Gregg W.
    Kimura, Takeshi
    Gao, Runlin
    Kereiakes, Dean J.
    Ellis, Stephen G.
    Onuma, Yoshinobu
    Chevalier, Bernard
    Simonton, Charles
    Dressler, Ovidiu
    Crowley, Aaron
    Ali, Ziad A.
    Serruys, Patrick W.
    JAMA CARDIOLOGY, 2019, 4 (12) : 1261 - 1269
  • [26] Comparison of Early Clinical Outcomes Between ABSORB Bioresorbable Vascular Scaffold and Everolimus-Eluting Stent Implantation in a Real-World Population
    Costopoulos, Charis
    Latib, Azeem
    Naganuma, Toru
    Miyazaki, Tadashi
    Sato, Katsumasa
    Figini, Filippo
    Sticchi, Alessandro
    Carlino, Mauro
    Chieffo, Alaide
    Montorfano, Matteo
    Colombo, Antonio
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2015, 85 (01) : E10 - E15
  • [27] Three to four years outcomes of the absorb bioresorbable vascular scaffold versus second-generation drug-eluting stent: A meta-analysis
    Goel, Sunny
    Pasam, Ravi Teja
    Chava, Srilekha
    Sharma, Abhishek
    Malik, Bilal Ahmad
    Ayzenberg, Sergey
    Frankel, Robert
    Shani, Jacob
    Gidwani, Umesh
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2020, 95 (02) : 216 - 223
  • [28] The Absorb bioresorbable vascular scaffold in real-world practice: long-term follow-up of the AMC Single Centre Real World PCI Registry
    Tijssen, R. Y. G.
    Annink, M. E.
    Kraak, R. P.
    Koch, K. T.
    Baan, J., Jr.
    Vis, M. M.
    Piek, J. J.
    Henriques, J. P. S.
    de Winter, R. J.
    Beijk, M. A. M.
    Wykrzykowska, J. J.
    NETHERLANDS HEART JOURNAL, 2020, 28 (03) : 153 - 160
  • [29] Long-term clinical results of bioresorbable absorb scaffolds using the PSP-technique in patients with and without diabetes
    Markovic, Sinisa
    Kugler, Christine
    Rottbauer, Wolfgang
    Wohrle, Jochen
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2017, 30 (04) : 325 - 330
  • [30] Long-term outcome of first 300 implanted Absorb bioresorbable vascular scaffolds in an all-comers Middle East population
    Al Nooryani, Arif
    Elabbassi, Wael N.
    AlBaba, Bassam
    Kerfes, Jalal A.
    Abudaqa, Loai M.
    Bhatia, Amit
    Abdelrahman, Nagwa A.
    Boskovic, Nikola
    Beleslin, Branko
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (01) : 173 - 187